The outlook of companies tied to Viagra's history presents a challenging investment landscape. While the initial surge generated substantial profits , generic copies have significantly eroded revenue. Investing in connected pharmaceutical businesses now requires a careful assessment of patent protection , evolving patient changes, and the prospect